Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study

Chun-Hua Wang, Pai-Chien Chou, Wen-Ching Joa, Li-Fei Chen, Te-Fang Sheng, Shu-Chuan Ho, Horng-Chyuan Lin, Chien-Da Huang, Fu-Tsai Chung, Kian Fan Chung, Han-Pin Kuo, Chun-Hua Wang, Pai-Chien Chou, Wen-Ching Joa, Li-Fei Chen, Te-Fang Sheng, Shu-Chuan Ho, Horng-Chyuan Lin, Chien-Da Huang, Fu-Tsai Chung, Kian Fan Chung, Han-Pin Kuo

Abstract

Background: Moderate-intensity exercise training improves skeletal muscle aerobic capacity and increased oxidative enzyme activity, as well as exercise tolerance in COPD patients.

Methods: To investigate whether the home-based exercise training program can reduce inflammatory biomarkers in patients with COPD, twelve patients using mobile phone assistance and 14 with free walk were assessed by incremental shuttle walk test (ISWT), spirometry, strength of limb muscles, and serum C-reactive protein (CRP) and inflammatory cytokines.

Results: Patients in the mobile phone group improved their ISWT walking distance, with decrease in serum CRP after 2 months, and sustained at 6 months. Patients in the control group had no improvement. Serum IL-8 in the mobile phone group was significantly reduced at 2, 3 and 6 months after doing home exercise training compared to baseline. IL-6 and TNF-α were significantly elevated at 3 and 6 months in control group, while there were no changes in mobile phone group. The strength of limb muscles was significantly greater compared to baseline at 3 and 6 months in the mobile phone group.

Conclusions: A mobile-phone-based system can provide an efficient home endurance exercise training program with improved exercise capacity, strength of limb muscles and a decrease in serum CRP and IL-8 in COPD patients. Decreased systemic inflammation may contribute to these clinical benefits. (Clinical trial registration No.: NCT01631019).

Figures

Figure 1
Figure 1
Incremental shuttle walking test (ISWT) was performed in the mobile phone group (N = 12) and the control group (N = 14) at baseline and after 1, 2, 3, 6 months. The sample size was 12 in the mobile phone group and 14 in the control group at each time point. Results are shown as mean ± SE. *P < 0.05, **P < 0.01 compared to the baseline. #P < 0.05 compared to the control group.
Figure 2
Figure 2
Plasma levels of C-reactive protein (CRP) were measured in the mobile phone group and control group at baseline, 1, 2, 3 and 6 months. The sample size was 12 in the mobile phone group and 14 in the control group at each time point. *P < 0.05, **P < 0.01, ***P < 0.001compared with the baseline level of corresponding group. #P < 0.05 compared to the control group.
Figure 3
Figure 3
Plasma levels of interleukin (IL)-8 were measured at baseline, 1, 2, 3 and 6 months in the mobile phone group (n = 12) and the control group (n = 14). *P < 0.05, **P < 0.01 compared to the baseline level of the mobile phone. #P < 0.01 compared to the control group at the same time point.
Figure 4
Figure 4
Plasma levels of (A) tumor necrosis factor (TNF)-α and (B) interleukin (IL)-6 were measured at baseline, 1, 2, 3, 6 months in both groups. The sample size was 12 in the mobile phone group and 14 in the control group at each time point. *P < 0.05, **P < 0.01 ***p < 0.001 compared to the baseline levels of the control group.

References

    1. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64. doi: 10.1164/rccm.201309-1634ST.
    1. Barreiro E, Criner GJ. Update in chronic obstructive pulmonary disease 2013. Am J Respir Crit Care Med. 2014;189(11):1337–1344. doi: 10.1164/rccm.201402-0245UP.
    1. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580. doi: 10.1136/thx.2003.019588.
    1. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax. 2002;57(12):1067–1070. doi: 10.1136/thorax.57.12.1067.
    1. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi: 10.1161/01.CIR.0000056767.69054.B3.
    1. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483. doi: 10.1371/journal.pone.0037483.
    1. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung. 2008;186(6):403–409. doi: 10.1007/s00408-008-9106-6.
    1. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61(10):849–853. doi: 10.1136/thx.2006.059808.
    1. Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J. EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010;11(1):63. doi: 10.1186/1465-9921-11-63.
    1. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006;61(1):10–16.
    1. Coronell C, Orozco-Levi M, Mendez R, Ramirez-Sarmiento A, Galdiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J. 2004;24(1):129–136. doi: 10.1183/09031936.04.00079603.
    1. Mador MJ, Bozkanat E, Kufel TJ. Quadriceps fatigue after cycle exercise in patients with COPD compared with healthy control subjects. Chest. 2003;123(4):1104–1111. doi: 10.1378/chest.123.4.1104.
    1. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):349–355. doi: 10.1164/ajrccm.163.2.2003122.
    1. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60(4):293–300. doi: 10.1136/thx.2004.027946.
    1. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58(9):752–756. doi: 10.1136/thorax.58.9.752.
    1. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387–395. doi: 10.1136/thx.2003.008730.
    1. van Eeden SF, Yeung A, Quinlam K, Hogg JC. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):61–67. doi: 10.1513/pats.200406-035MS.
    1. Mercken EM, Hageman GJ, Schols AM, Akkermans MA, Bast A, Wouters EF. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(8):994–1001. doi: 10.1164/rccm.200411-1580OC.
    1. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest. 2005;128(4):2025–2034. doi: 10.1378/chest.128.4.2025.
    1. Demirbag R, Yilmaz R, Guzel S, Celik H, Koçyigit A, Ozcan E. Effects of treadmill exercise test on oxidative/antioxidative parameters and DNA damage. Anadolu Kardiyol Derg. 2006;6(2):135–140.
    1. Koppers RJ, Vos PJ, Boot CR, Folgering HT. Exercise performance improves in patients with COPD due to respiratory muscle endurance training. Chest. 2006;129(4):886–892. doi: 10.1378/chest.129.4.886.
    1. Maltais F, Bourbeau J, Lacasse Y, Shapiro S, Perrault H, Penrod JR, Baltzan M, Rouleau M, Julien M, Paradis B, Audet R, Hernandez P, Levy RD, Camp P, Lecours R, Picard D, Bernard S. A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods. Can Respir J. 2005;12(4):193–198.
    1. Liu WT, Wang CH, Lin HC, Lin SM, Lee KY, Lo YL, Hung SH, Chang YM, Chung KF, Kuo HP. Efficacy of a cell phone-based exercise programme for COPD. Eur Respir J. 2008;32(3):651–659. doi: 10.1183/09031936.00104407.
    1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi: 10.1164/rccm.201204-0596PP.
    1. Singh SJ, Morgan MD, Hardman AE, Rowe C, Bardsley PA. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J. 1994;7(11):2016–2020.
    1. Chiang LL, Wang LY, Wu CP, Wu HD, Wu YT. Effects of physical training on functional status in patients with prolonged mechanical ventilation. Phys Ther. 2006;86(9):1271–1281. doi: 10.2522/ptj.20050036.
    1. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, Guralnik JM, Ferrucci L. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–248. doi: 10.1093/gerona/59.3.M242.
    1. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med. 2000;21(1):21–24. doi: 10.1055/s-2000-8852.
    1. Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ, Marsh AP, Kritchevsky SB, Nicklas BJ. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci. 2009;64(4):455–461.
    1. Casaburi R. Impacting patient-centred outcomes in COPD: deconditioning. Eur Respir Rev. 2006;15:42–46. doi: 10.1183/09059180.00009904.
    1. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2001;11(9):607–615.
    1. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166(9):1218–1224. doi: 10.1164/rccm.2202023.
    1. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347–360. doi: 10.1183/09031936.03.00405703.
    1. Paredi P, Kharitonov SA, Leak D, Sala E, Pons J, Busquets X. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(2 Pt 1):369–373.
    1. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner CF. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;12(2):380–386. doi: 10.1183/09031936.98.12020380.
    1. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001;18(Suppl 34):50S–59S.
    1. Gigliotti F, Coli C, Bianchi R, Romagnoli I, Lanini B, Binazzi B, Scano G. Exercise training improves exertional dyspnea in patients with COPD: evidence of the role of mechanical factors. Chest. 2003;123(6):1794–1802. doi: 10.1378/chest.123.6.1794.
    1. Allaire J, Maltais F, Doyon JF, Noël M, LeBlanc P, Carrier G, Simard C, Jobin J. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax. 2004;59(8):673–678. doi: 10.1136/thx.2003.020636.
    1. Agustí AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):367–370. doi: 10.1513/pats.200504-026SR.
    1. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J. 2005;26(4):703–719. doi: 10.1183/09031936.05.00139904.
    1. Vogiatzis I, Stratakos G, Simoes DC, Terzis G, Georgiadou O, Roussos C, Zakynthinos S. Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax. 2007;62(11):950–956. doi: 10.1136/thx.2006.069310.
    1. Moy ML, Teylan M, Weston NA, Gagnon DR, Danilack VA, Garshick E. Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. Chest. 2014;145(3):542–550. doi: 10.1378/chest.13-1052.
    1. Young RP, Hopkins RJ. Interleukin-6 and statin therapy: potential role in the management of COPD. Respir Res. 2013;14(1):74. doi: 10.1186/1465-9921-14-74.
    1. Ferrari R, Tanni SE, Caram LM, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):24. doi: 10.1186/1465-9921-14-24.
    1. Wijkstra PJ, Ten Vergert EM, van Altena R, Otten V, Kraan J, Postma DS, Koëter GH. Long term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax. 1995;50(8):824–828. doi: 10.1136/thx.50.8.824.
    1. Spencer LM, Alison JA, McKeough ZJ. Do supervised weekly exercise programs maintain functional exercise capacity and quality of life, twelve months after pulmonary rehabilitation in COPD? BMC Pulm Med. 2007;7:7. doi: 10.1186/1471-2466-7-7.
    1. Eaton T, Young P, Nicol K, Kolbe J. The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients. Chron Respir Dis. 2006;3(1):3–9. doi: 10.1191/1479972306cd077oa.
    1. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation physiological and psychological outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995;122(11):823–832. doi: 10.7326/0003-4819-122-11-199506010-00003.
    1. Maltais F, LeBlanc P, Jobin J, Bérubé C, Bruneau J, Carrier L, Breton MJ, Falardeau G, Belleau R. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155(2):555–561. doi: 10.1164/ajrccm.155.2.9032194.
    1. Mercken EM, Gosker HR, Rutten EP, Wouters EF, Bast A, Hageman GJ, Schols AM. Systemic and pulmonary oxidative stress after single-leg exercise in COPD. Chest. 2009;136(5):1291–1300. doi: 10.1378/chest.08-2767.
    1. van Helvoort HA, van de Pol MH, Heijdra YF, Dekhuijzen PN. Systemic inflammatory response to exhaustive exercise in patients with chronic obstructive pulmonary disease. Respir Med. 2005;99(12):1555–1567. doi: 10.1016/j.rmed.2005.03.028.
    1. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med. 2003;167(6):880–888. doi: 10.1164/rccm.200204-318OC.
    1. Waterhouse JC, Walters SJ, Oluboyede Y, Lawson RA. A randomised 2 x 2 trial of community versus hospital pulmonary rehabilitation, followed by telephone or conventional follow-up. Health Technol Assess. 2010;14(6):1–164.
    1. Wijkstra PJ, van der Mark TW, Postma DS, Van Altena R, Kraan J, Koëter GH. Long-term effects of home rehabilitation on physical performance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(4 Pt 1):1234–1241.
    1. Strijbos JH, Postma DS, van Altena R, Gimeno F, Koëter GH. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest. 1996;109(2):366–372. doi: 10.1378/chest.109.2.366.
    1. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1998;12(2):363–369. doi: 10.1183/09031936.98.12020363.
    1. Arnold E, Bruton A, Ellis-Hill C. Adherence to pulmonary rehabilitation: a qualitative study. Respir Med. 2006;100(10):1716–1723. doi: 10.1016/j.rmed.2006.02.007.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться